April 23- Spectrum Pharmaceuticals Inc said it expects to seek U.S. marketing approval for its blood cancer drug in the third quarter, after the treatment was shown to be safe and effective in a key mid-stage trial. Roth Capital Partners analyst Joseph Pantginis said he expects CE-Melphalan to receive full approval next year.» Read More
April 22- Amgen Inc on Tuesday reported lower-than-expected first quarter profit as sales of several key products fell short of Wall Street estimates, with its big-selling rheumatoid arthritis drug Enbrel particularly hard hit by inventory stocking by wholesalers late last year.
April 22- Gilead Sciences Inc, which ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2.27 billion, helping the company's quarterly net profit nearly triple.
April 22- Gilead Sciences Inc, whose pricing policy ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2.27 billion, helping the company's quarterly net profit nearly triple.
*Novartis to buy GSK's oncology assets for $14.5 bln. The deals, which include Novartis buying GSK's cancer drugs and GSK acquiring Novartis' vaccines business, came hot on the heels of a newspaper report that AstraZeneca had turned down a $101 billion bid approach from Pfizer- a story that sent shares across the sector surging.
*Novartis to buy GSK's oncology assets for $14.5 bln. *Lilly to buy Novartis' animal health arm for $5.4 bln.
Pfizer Inc may come back to bid for British drug company AstraZeneca Plc after its reported 60 billion pound takeover approach was rejected.
Sarepta Therapeutics CEO Chris Garabedian discusses the prospects for what he calls a "potential accelerated approval" for its Duchenne muscular dystrophy drug Eteplirsen.
Sarepta Therapeutics is developing a drug for Duchenne muscular dystrophy. Its CEO Chris Garabedian discusses challenges the drug Eteplirsen has faced before the FDA.
*Plans to file for eteplirsen approval by end of 2014. April 21- Sarepta Therapeutics Inc's shares soared 64 percent after it said that the U.S. Food and Drug Administration indicated an alternate path to approval for the company's experimental muscle disorder drug.
As marijuana safety concerns grow, Stephen Shearin, Tranzbyte COO, discusses his company's age verification marijuana vending machine for medicinal users.
The company hit a roadblock late last year when the health regulator said the design and goals of the previous trial may not be sufficient, citing new data on DMD and the failed trial of a competing drug made by Prosensa Holding NV.
LONDON, April 21- Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise.
RIYADH, Saudi Arabia— Saudi Arabia's King Abdullah sacked the country's health minister on Monday amid a spike in deaths and infections from the virus known as the Middle East respiratory syndrome, or MERS.
CHICAGO— A jury has awarded $14 million to a suburban Chicago woman who said in a lawsuit that she suffered a debilitating stroke after taking the birth control drug Yasmin. Friday's verdict came after a two-week trial in Cook County Circuit Court. A $2.5 million settlement in the same matter was reached a month ago with the hospital, Resurrection Medical Center.
April 18- Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually.
Some medical groups now want doctors to consider both the effectiveness and costs of treatment options.
April 17- The U.S. Food and Drug Administration has approved Merck& Co's pollen allergy drug Ragwitek. The tablet, which is administered by placing it under the tongue, is to treat the short ragweed pollen induced allergic rhinitis.
CNBC's Meg Tirrell reports on a new scientific discovery for the more than $1.7 billion U.S. business of in vitro fertilization. Robert Frank provides insight.
April 17- The U.S. Food and Drug Administration warned that a surgical procedure used to mince uterine fibroids and remove them through a tiny abdominal incision could spread cancer tissue beyond the uterus in women with undetected uterine cancer.
WASHINGTON— The Food and Drug Administration is warning women that a surgical procedure used to eliminate growths in the uterus could inadvertently spread cancer to other parts of the body.